Across pharma, biotech, CROs, MedTech, research sites, and investors — each one trading manual database-hopping for one source-traceable, always-current view.
Every page maps the recurring weekly work to what ClinicaLister does about it, on which surface, and what it does not do yet.
Portfolio oversight across dozens of active trials
Your whole portfolio in one always-current view, with field-level alerts within hours whenever any trial shifts status, enrollment, or timeline — across every study you follow and every competitor you watch.
Tracking competitor pipelines, approvals, and IP
Trials arrive already linked to their FDA and EMA approvals, comparative safety, and shortage signals, with every change flagged within hours and a source behind every claim — intelligence you can hand to the board without re-checking it.
Regulatory status, designations, and change tracking
Approval status, current label, REMS and orphan designation sit right next to the trial — aggregated across your whole portfolio and every competitor, with every field-level change flagged and graded.
Running many trials across many sponsors
Every trial, across every sponsor, in one dashboard — with an alert the moment a registry field moves and a one-click, sponsor-ready export. No more portal-hopping.
Therapeutic-area strategy and the MSL team
See the whole therapeutic landscape, not just individual trials — emerging drug classes, biosimilar pipelines, safety signals, and exactly where competitors are focusing, all in one place.
Clean, cross-linked data for the analytics team
Trials, drugs, devices, substances, and US/EU registries arrive already linked — each connection tagged with how it was matched and how confident that match is. Ready to export for your analysts or query straight from an AI agent. Stop building pipelines; start analyzing.
Enrollment and referrals at the research site
Every trial at your site — and every recruiting study nearby — on one map, with an alert the moment status or eligibility changes on a trial you follow, and a draw-on-the-map filter that turns a screen-fail into a referral shortlist in a single pass.
Strategic portfolio oversight and board reporting
Phase balance, geographic exposure, portfolio churn, and competitor concentration in one real-time dashboard — the whole portfolio at a glance, drillable to a single trial in a click, current the moment you open it.
Field scientific engagement with KOLs and investigators
One sourced brief per KOL in minutes — their trials, publications, endpoints, and safety and label context — plus a map of the investigators and evidence in your territory, so you walk in prepared and credible.
Pipeline, IP, and market risk across many companies
Point your AI assistant at any public sponsor and get a sourced pipeline, competition, safety and market-risk brief in minutes — with a Medicare spend proxy to size what each asset is exposed to.
Pricing, Medicare spend, and reimbursement evidence
Acquisition cost, ASP, Medicare spend, transparency payments, and shortages assembled into one sourced pricing view beside the drug — the only place these public pillars come together, every figure traced to its CMS or FDA origin.
FDA device intelligence — clearance, recalls, MAUDE, GUDID
The whole FDA device dossier on one screen — 510(k)/PMA clearance, classification, GUDID identity, recalls, adverse-event signals, and registrations — with predicate-and-recall analysis and confidence-scored links from each device to the trials that cite it.
Exploring the biology, evidence, and study landscape
Trace a mechanism to the clinic in one thread: the molecules that hit a target or share a drug class, the diseases they touch, and the trials testing them — with chemical identity attached, disease-taxonomy landscapes, and sourced maps of where the evidence runs out.